Isolated Addison's disease is unlikely to be caused by mutations in MC2R, MRAP or STAR, three genes responsible for familial glucocorticoid deficiency by Dias, RP et al.
European Journal of Endocrinology (2010) 162 357–359 ISSN 0804-4643CLINICAL STUDY
Isolated Addison’s disease is unlikely to be caused by mutations
in MC2R, MRAP or STAR, three genes responsible for familial
glucocorticoid deficiency
R P Dias, L F Chan, L A Metherell, S H S Pearce1 and A J L Clark
Barts and the London School of Medicine and Dentistry, Centre for Endocrinology, John Vane Science Centre, Queen Mary University of London,
Charterhouse Square, London EC1M 6BQ, UK and 1Institute of Human Genetics, Centre for Life, Newcastle University, Central Parkway,
Newcastle upon Tyne NE1 3BZ, UK
(Correspondence should be addressed to A J L Clark; Email: a.j.clark@qmul.ac.uk)q 2010 European Society of E
This is an Open Access artic
non-commercial use, distributioAbstract
Background: Familial glucocorticoiddeficiency (FGD) is a rareautosomal recessive disease causedbyACTH
resistance and leads to isolated glucocorticoid deficiency. Although FGD patients typically have normal
mineralocorticoid secretion, subtle alterations in the renin–angiotensin–aldosterone axis have been
reported in a subset of patients at presentation. Anecdotally, some patients with FGD have been initially
diagnosed as having Addison’s disease (AD), with implications for treatment and genetic counselling.
Currently, mutations in three genes: the ACTH receptor (MC2R); the melanocortin 2 receptor accessory
protein (MRAP); and the steroidogenic acute regulatory protein (STAR) are known to give rise to FGD
types 1–3. We investigated a cohort of autoantibody-negative AD patients for mutations in these genes.
Methods: Forty patients with known AD without evidence of autoimmune disease were screened for
mutations in MC2R, MRAP and STAR. In addition, patients were genotyped for the MC2R promoter
polymorphism previously associated with reduced responsiveness to ACTH.
Results: No mutations in MC2R, MRAP or STAR were identified in any patient. The frequencies of the
MC2R promoter polymorphism were similar to those reported in healthy controls.
Conclusions: FGD does not appear to be underdiagnosed in the AD population. However, in w50% of
patients with FGD, no genetic cause has yet been identified and it is possible that the other, as yet
unidentified, genes giving rise to FGD may be implicated in AD.
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Primary adrenal failure is relatively rare with a
prevalence of approximately five cases per 100 000 in
Northern Europe (1, 2). The initial cases described
by Addison in 1855 involved tuberculosis, adrenal
malignancy and idiopathic adrenal fibrosis, which is
now thought to be the first report of autoimmune
adrenal disease (3). Currently, autoimmune Addison’s
disease (AAD) accounts for the majority of cases of
primary adrenal failure inwestern countries (up to 94%)
(1). AAD can occur either in conjunction with other
autoimmune conditions (autoimmune polyendocrine
syndromes), or in isolation. Isolated AAD with no other
autoimmune clinical manifestations occurs in about
40% of cases, but positive autoantibodies have been
shown to be present in up to 80% of these (4).
Primary adrenal insufficiency (or antibody-negative
AD) covers a broad spectrum of pathologies including
malignant, infectious and genetic causes. Genetic
causes range from autosomal or X-linked recessive
conditions such as familial ACTH resistance syndromesndocrinology
le distributed under the terms of the Europea
n, and reproduction in any medium, provided th(familial glucocorticoid deficiency (FGD), Triple A),
congenital adrenal hyperplasia and adrenoleukodys-
trophy to mitochondrial disorders such as Kearns-
Sayres syndrome.
FGD (OMIM 202200) is an autosomal recessive
condition characterised by ACTH resistance leading
to isolated glucocorticoid deficiency with normal
mineralocorticoid secretion. The syndrome was first
described by Shepard et al. in 1959 in two siblings
who had initially been diagnosed with AD (5). However,
although patients with FGD have normal renin and
aldosterone levels, subtle abnormalities of the renin–
angiotensin axis are sometimes seen in this condition
at diagnosis, most notably with nonsense mutations
of the ACTH receptor (MC2R) (6, 7). In contrast, the
recently described MC2R knockout mouse model
demonstrates classical adrenal failure with both gluco-
corticoid and mineralocorticoid deficiency (8).
The first inactivating mutation of the MC2R (also
known as the melanocortin type 2 receptor) in a patient
with FGD was reported in 1993 (9), and subsequently
more than 30 mutations in the MC2R have beenDOI: 10.1530/EJE-09-0720
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promoter at position2was described ashaving decreased
response to ACTH both in vitro and in normal human
subjects following i.v. ACTH infusion (11).More recently,
mutations in a novel gene, the melanocortin 2 receptor
accessory protein (MRAP), which is involved in
trafficking MC2R to the plasma membrane, have been
described in FGD (12). In 2009, Metherell et al. reported
that a proportion of patients with FGD (5–10%) have
mutations in STAR (13). STAR mutations usually give
rise to a severe form of adrenal insufficiency known as
lipoid congenital adrenal hyperplasia (LCAH; OMIM
201701), leading to both mineralocorticoid and gluco-
corticoid deficiency. Mutations in these three genes lead
to FGD types 1, 2 and 3 respectively and account for just
over 50% of all known clinical cases of FGD. Further-
more, there are reports of patients initially diagnosed
with AD subsequently having their diagnosis refined to
FGD, allowing them to omit their mineralocorticoid
replacement therapy (5). Of note, two families found to
have STAR mutations leading to adrenal failure were
initially diagnosed with non-AAD. Having noted that
there appear to be certain mutations inMC2R and STAR
causing adrenal failure with both mineralocorticoid and
glucocorticoid abnormalities, we investigated here the
possibility that a subset of patients with isolated AD
without evidence of autoimmune disease may have
mutations in MC2R, MRAP or STAR. In addition, we
screened the AD cohort for possible increased frequency
of the MC2R promoter polymorphism associated with
reduced responsiveness to ACTH.Subjects and methods
Patients
Forty patients (17 males and 23 females) with isolated
AD were identified from a previously described cohort of
patients studied in the north-east of England (14). The
mean age of diagnosis was 36.5 years (range 8–79
years). All patients demonstrated a peak cortisol
response of !550 nmol/l following a short synacthen
test (250 mg synthetic ACTH administered i.m). All
patients had a diagnosis of primary adrenal failure
(secondary adrenal failure, infiltrative and infective
causes were excluded). All patients with evidence of
autoimmune disease or polyendocrinopathy (positive
adrenal autoantibody screen by immunofluorescence or
other organ system affected, e.g. thyroid dysfunction,
vitiligo, type 1 diabetesmellitus and pernicious anaemia)
were excluded. Patients with any family history of
autoimmune disease were excluded. No patient had
formal investigation of the renin–angiotensin axis,
although none were known to have maintained normal
mineralocorticoid secretion. There was one familial case
of AD in the cohort (mother diagnosed at the age of
28 years and her son diagnosed at the age of 8).www.eje-online.orgDNA extraction
Genomic DNA was extracted from whole blood using
the Nucleon BACC DNA extraction kit according
to the manufacturer’s instructions (GE Healthcare,
Buckinghamshire, UK).Sequencing
MC2R has a single-coding exon. It has previously been
reported that the majority of the mutations in MRAP
in FGD patients are in exon 3. Exon 5 of STAR is
where all mutations in non-classical LCAH and/or FGD
have been described (6, 13, 15), whereas mutations
found in other exons in this gene cause the classical
LCAH phenotype.
PCRwas carried out using published primers directed
to intronic sequences to cover the coding exon ofMC2R,
exon 3 ofMRAP and exons 5 and 6 of STAR in the entire
AD cohort (12, 13). Cycling conditions were 95 8C for
5 min (1 cycle); 95 8C for 30 s, 55 8C for 30 s and 72 8C
for 30 s (30 cycles); and 72 8C for 5 min. PCR products
were visualized on 1% agarose gel, and PCR fragments
were sequenced using the ABI Prism Big Dye Sequen-
cing kit and an ABI 3700 automated DNA sequencer
(Applied Biosystems, Foster City, CA, USA) in accord-
ance with the manufacturer’s instructions.Genotyping
PCR was carried using previously published primers
around the K2 MC2R promoter polymorphism (11).
PCR products were digested with Sac1 giving three
possible genotypes (CTC/CTC homozygote, CTC/CCC
heterozygote and CCC/CCC homozygote), when run
on a 2% agarose gel as previously reported. To confirm
the accuracy of restriction enzyme digestion, conven-
tional sequencing of three apparent homozygotes
for both alleles and three heterozygotes was carried
out as above.Results
No mutations in MC2R, MRAP or STAR were identified
in any patient. There were no single nucleotide
polymorphisms (SNPs) identified in the MC2R coding
exon, but a number of individuals had a previously
reported intronic SNP (rs2254251) downstream of
exon 3 of MRAP.
For the promoter polymorphism inMC2R, the C allele
frequency in our patient population was 0.112 (9/80),
which is comparable with the HapMap CEPH SNP
database C allele frequency of 0.117. In the AD cohort
studied, frequencies of MC2R promoter polymorphism
were not significantly different to previously reported
frequencies in normal controls using c2 test with 2 d.f.:
CTC/CTC 71.0% (80.2%); CTC/CCC 26.4% (19.0%) and
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describe reported frequencies in healthy controls (11).
The population studied was in Hardy–Weinberg
equilibrium.Discussion
AD is a common cause of adrenal failure in adults. In
our cohort of FGD patients and other reported patients
with non-classical LCAH, there are several reports of
family members diagnosed initially with Addison’s
disease or with late onset of symptoms of glucocorticoid
deficiency who have subsequently been found to have
mutations in MC2R or STAR with alterations in their
renin–angiotensin–aldosterone axis. However, our
results indicate that FGD is not being underdiagnosed
within the wider AD population in the UK. Further-
more, there does not appear to be any significant
increase in the MC2R promoter polymorphism
consistent with reduced responsiveness to ACTH,
consistent with other Caucasian populations previously
reported (11, 16, 17), although we accept that a
detailed analysis of a local control population would be
desirable. However, it may be that in other regions,
mutation screening for FGD is not considered perhaps
because of an atypical biochemical profile or resource
considerations, and consequently such patients are
being diagnosed as having antibody negative AD.
Nevertheless, mutations in these genes account for
only just over 50% of cases of FGD. It is known that
there are several further loci involved in FGD and there
is phenotypic variability in patients with FGD of
unknown cause (18). It is possible that as yet
unidentified gene(s) for FGD could account for familial
cases of non-AAD.
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